UN High Commission on Access to Medicines: Incentives, Agreements and Stockpiling to Accelerate the Response to Infectious Disease Outbreaks | Duke Kunshan University
UN High Commission on Access to Medicines: Incentives, Agreements and Stockpiling to Accelerate the Response to Infectious Disease Outbreaks
Speaker: 
Jeffrey Moe

Jeffrey Moe, Professor of the Practice, Duke Global Health Institute, Duke University

Mar 17th 2016 12:00 to 13:00
Room 1079, Academic Building

Summary of Talk:

Jeffrey Moe is Professor of the Practice in Global Health, DKU and Duke University. With colleagues, David Ridley and Henry Grabowski, he wrote the seminal article, "Developing Drugs for Developing Countries" (March/April Health Affairs, 2006) which led to the creation of the FDA's "priority review voucher" (PRV) program. PRV rewards discovery of new therapeutics to treat high burden global diseases. To date 10 vouchers have been awarded and the value that Moe, Ridley and Grabowski estimated in 2006, >$300 million, has been established by the exchanges of vouchers that have occurred 2008 - 2015. Recently Moe and Ridley have been engaged by the International Vector Control Consortium. They are conducting an analysis to extrapolate the priority review voucher concept to pesticides for vector control: a voucher for expedited review by the US Environmental Protection Agency as a prize for new vector control agents that are safe and effective against global disease vector pests (e.g. mosquitoes). Professor Moe will discuss the initial approach to incentives for vector control. Moe was an invited participant to the March 10 Global Dialogue convened by the UN High Commission on Access to Medicines. The Commission will deliver its report in June on new approaches to drug surveillance, innovation and accessibility. Professor Moe will discuss his presentation to the High Commission and the dialogue that occurred in London.

 

Brief Biography:

Jeffrey Moe is Professor of the Practice, Duke Global Health Institute, Duke University. Prior to joining DGHI he spent 13 years with a primary appointment in the Fuqua School of Business, Health Sector Management program, Duke University. His research interests include incentives to stimulate research and development of new medicines for global diseases; identification and replication of health care delivery innovation, life-saving commodities (e.g. chlorhexidine for umbilical cord care) and ethical issues relating to patient access to new medicines and public private partnerships. Moe also has a faculty appointment at the Duke Kunshan University in Kunshan, China.

Before coming to Duke, Moe was an executive at GlaxoSmithKline. Over a 15-year career he held positions in business development, corporate strategy, marketing, market economics and human resources. In 1997 he was seconded to South Africa to assist the local operating company to develop new strategies for large purchasers (i.e. government, “managed care”, hospitals, employers) of Glaxo products. More recently, December 2013 – June, 2014 Moe resided in Shanghai, China. During that residency he prepared for teaching at the Duke Kunshan University (Kunshan, China campus) and continued research on health delivery innovators, challenges and opportunities for the Chinese biopharmaceutical industry and observations on the challenges facing hospitals and other health deliverers in the current Chinese post-reform period. Moe is advising the State Council of China on reforms to the China national and provincial policies for drug procurement, distribution and pricing.

oe received his Ph.D. in Organization Development and Institutional Studies from the University of North Carolina at Chapel Hill, 1981. He received a certificate from the Kellogg School, Northwestern University, Executive Development Program in 1997. Moe has previously been a lecturer at the University of Witwatersrand in Johannesburg, South Africa.